SCHEMBL373295

SCHEMBL373295

C[C@@H]1OCCN(c2nc(N3CCCCC3)nc(-n3c(N)nc4ccccc43)n2)[C@@H]1C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CB P42338 13/20 0.46
PIK3CA P42336 6/20 0.46
PIK3CD O00329 4/20 0.46
PIK3CG P48736 4/20 0.46
ATR Q13535 4/20 0.43
PIK3C2B O00750 1/20 0.42
PIK3R1 P27986 1/20 0.42
MTOR P42345 1/20 0.42
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
HTT P42858 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL373297 1.00 PIK3CB (0.46) PIK3CBPIK3CAPIK3CDPIK3CGATR
SCHEMBL373296 1.00 PIK3CB (0.46) PIK3CBPIK3CAPIK3CDPIK3CGATR
SCHEMBL373616 0.92 PIK3CB (0.58) PIK3CBPIK3CAPIK3CDPIK3CGATR
SCHEMBL373615 0.92 PIK3CB (0.58) PIK3CBPIK3CAPIK3CDPIK3CGATR
SCHEMBL373617 0.92 PIK3CB (0.58) PIK3CBPIK3CAPIK3CDPIK3CGATR
SCHEMBL373393 0.81 ATR (0.58) PIK3CBPIK3CAPIK3CDPIK3CGATR
SCHEMBL373392 0.81 ATR (0.58) PIK3CBPIK3CAPIK3CDPIK3CGATR
SCHEMBL373440 0.81 ATR (0.58) PIK3CBPIK3CAPIK3CDPIK3CGATR
SCHEMBL373441 0.81 ATR (0.58) PIK3CBPIK3CAPIK3CDPIK3CGATR
SCHEMBL373391 0.81 ATR (0.58) PIK3CBPIK3CAPIK3CDPIK3CGATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071189-B2 Heterocyclic compound and antitumor agent containing the same as active ingredient ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2006-07-04 US claimed
EP-2409975-B1 Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound ZENYAKU KOGYO KK (JP) 2015-05-27 EP disclosed
US-8227463-B2 Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2012-07-24 US disclosed
EP-2409975-A1 Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-01-25 EP disclosed
US-20100249063-A1 AMORPHOUS BODY COMPOSED OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND PHARMACEUTICAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2010-09-30 US disclosed
EP-2218718-A1 AMORPHOUS FORM OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND MEDICINAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2010-08-18 EP disclosed
US-7307077-B2 Heterocyclic compound and antitumor agent containing the same as effective ingredient ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2007-12-11 US disclosed
EP-1389617-B1 HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT ZENYAKU KOGYO KK (JP) 2007-01-03 EP disclosed
US-20060247232-A1 Heterocyclic compound and antitumor agent containing the same as effective ingredient ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2006-11-02 US disclosed
US-7071189-B2 Heterocyclic compound and antitumor agent containing the same as active ingredient ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2006-07-04 US disclosed
US-20040116421-A1 Heterocyclic compound and antitumor agent containing the same as active ingredient OHARA PHARMACEUTICAL CO., LTD. (JP) 2004-06-17 US disclosed
EP-1389617-A1 HETEROCYCLIC COMPOUND AND ANTITUMOR AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2004-02-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249063-A1 AMORPHOUS BODY COMPOSED OF HETEROCYCLIC COMPOUND, SOLID DISPERSION AND PHARMACEUTICAL PREPARATION EACH COMPRISING THE SAME, AND PROCESS FOR PRODUCTION OF THE SAME SBDS, ABCG2, SSRP1 PIK3CB 4109/4885PIK3CA 3548/4885PIK3CD 4060/4885
US-20060247232-A1 Heterocyclic compound and antitumor agent containing the same as effective ingredient CBR3, HCCS, CBR1 PIK3CB 3376/4885PIK3CA 2412/4885PIK3CD 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.